{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:56Z","timestamp":1776408716794,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U24A20679"],"award-info":[{"award-number":["U24A20679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-0022"],"award-info":[{"award-number":["CIRP-SYSUCC-0022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06910-8","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:53:05Z","timestamp":1773467585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study"],"prefix":"10.1007","volume":"105","author":[{"given":"Zhangyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huangming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"1","key":"6910_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric Antigen Receptor Therapy. N Engl J Med 379(1):64\u201373","journal-title":"N Engl J Med"},{"key":"6910_CR2","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1182\/blood-2018-99-114434","volume":"132","author":"W Wang","year":"2018","unstructured":"Wang W et al (2018) JWCAR029 Is a CD19-Targeted CAR T Cell Product with Process and Quality Controls Delivered As a Flat Dose of CAR T Cell to Patients with NHL. Blood 132:5387","journal-title":"Blood"},{"issue":"10254","key":"6910_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852","journal-title":"Lancet"},{"issue":"26","key":"6910_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"1","key":"6910_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"10","key":"6910_CR6","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1080\/10428194.2020.1761967","volume":"61","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Park JH (2020) Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice. Leuk Lymphoma 61(10):2324\u20132334","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6910_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ et al (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"13","key":"6910_CR8","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY et al (2021) Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137(13):1832\u20131835","journal-title":"Blood"},{"issue":"24","key":"6910_CR9","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R et al (2022) Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood 140(24):2584\u20132593","journal-title":"Blood"},{"issue":"4","key":"6910_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/10428194.2019.1691201","volume":"61","author":"KE Cahill","year":"2020","unstructured":"Cahill KE, Leukam MJ, Riedell PA (2020) Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leuk Lymphoma 61(4):799\u2013807","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6910_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-024-01608-8","volume":"17","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G et al (2024) Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment. J Hematol Oncol 17(1):102","journal-title":"J Hematol Oncol"},{"issue":"9","key":"6910_CR12","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1007\/s00432-023-04587-4","volume":"149","author":"TW Georgi","year":"2023","unstructured":"Georgi TW et al (2023) Prognostic value of baseline and early response FDG-PET\/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. J Cancer Res Clin Oncol 149(9):6131\u20136138","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"6910_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","volume":"17","author":"D Leithner","year":"2024","unstructured":"Leithner D et al (2024) Conventional and novel [(18)F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma. J Hematol Oncol 17(1):21","journal-title":"J Hematol Oncol"},{"issue":"3","key":"6910_CR14","first-page":"159","volume":"31","author":"E Abadir","year":"2025","unstructured":"Abadir E et al (2025) Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies. Transpl Cell Ther 31(3):159\u2013165","journal-title":"Transpl Cell Ther"},{"key":"6910_CR15","doi-asserted-by":"publisher","first-page":"627764","DOI":"10.3389\/fimmu.2021.627764","volume":"12","author":"R Hong","year":"2021","unstructured":"Hong R, Hu Y, Huang H (2021) Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. Front Immunol 12:627764","journal-title":"Front Immunol"},{"issue":"12","key":"6910_CR16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.21037\/atm-20-5546","volume":"9","author":"M Narkhede","year":"2021","unstructured":"Narkhede M et al (2021) CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. Ann Transl Med 9(12):1036","journal-title":"Ann Transl Med"},{"key":"6910_CR17","doi-asserted-by":"publisher","first-page":"1378944","DOI":"10.3389\/fimmu.2024.1378944","volume":"15","author":"L Levstek","year":"2024","unstructured":"Levstek L et al (2024) Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives. Front Immunol 15:1378944","journal-title":"Front Immunol"},{"issue":"4","key":"6910_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3233\/CBM-160336","volume":"19","author":"J Ding","year":"2017","unstructured":"Ding J, Karp JE, Emadi A (2017) Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark 19(4):353\u2013363","journal-title":"Cancer Biomark"},{"issue":"16","key":"6910_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN et al (2017) Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol 35(16):1803\u20131813","journal-title":"J Clin Oncol"},{"issue":"6","key":"6910_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5483\/BMBRep.2017.50.6.056","volume":"50","author":"JH Um","year":"2017","unstructured":"Um JH, Yun J (2017) Emerging role of mitophagy in human diseases and physiology. BMB Rep 50(6):299\u2013307","journal-title":"BMB Rep"},{"issue":"9","key":"6910_CR21","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1007\/s00432-023-04587-4","volume":"149","author":"TW Georgi","year":"2023","unstructured":"Georgi TW et al (2023) Prognostic value of baseline and early response FDG-PET\/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. J Cancer Res Clin Oncol 149(9):6131\u20136138","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"6910_CR22","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K et al (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138(24):2499\u20132513","journal-title":"Blood"},{"issue":"22","key":"6910_CR23","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L et al (2020) Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv 4(22):5607\u20135615","journal-title":"Blood Adv"},{"issue":"8","key":"6910_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/annonc\/mdy203","volume":"29","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ et al (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29(8):1822\u20131827","journal-title":"Ann Oncol"},{"issue":"2","key":"6910_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41409-023-02176-0","volume":"59","author":"S El Warrak","year":"2024","unstructured":"El Warrak S et al (2024) Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. Bone Marrow Transpl 59(2):162\u2013170","journal-title":"Bone Marrow Transpl"},{"issue":"24","key":"6910_CR26","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood.2022018295","volume":"140","author":"JS Abramson","year":"2022","unstructured":"Abramson JS (2022) Post-CAR relapse in DLBCL: a fork in the road. Blood 140(24):2527\u20132529","journal-title":"Blood"},{"key":"6910_CR27","doi-asserted-by":"publisher","unstructured":"Erbella F, Bachy E, Cartron G, Gat E, Manson G, Morschhauser F, Gros FX, Roulin L, Tessoulin B, Bories P, Tournilhac O, Ricard L, Guidez S, Choquet S, Casasnovas RO, Brisou G, Campidelli A, Castilla-Llorente C, Jardin F, Gyan E, Guffroy B, Abraham J, Decroocq J, Chauchet A, Joris M, Claves F, Carras S, Guillerm G, Loschi M, Hermine O, Taguy-Schimidt A, Le Gouill S, Houot R, Di Blasi R. Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry. Blood Adv. 2026 Jan 27;10(2):392-401. https:\/\/doi.org\/10.1182\/bloodadvances.2025016727","DOI":"10.1182\/bloodadvances.2025016727"},{"key":"6910_CR28","doi-asserted-by":"crossref","unstructured":"Aymard M et al (2025) Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group. Blood Advances","DOI":"10.1182\/bloodadvances.2025017234"},{"issue":"15","key":"6910_CR29","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","volume":"9","author":"E Shumilov","year":"2025","unstructured":"Shumilov E et al (2025) Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. Blood Adv 9(15):3955\u20133966","journal-title":"Blood Adv"},{"issue":"24","key":"6910_CR30","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R et al (2022) Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood 140(24):2584\u20132593","journal-title":"Blood"},{"issue":"2","key":"6910_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41409-024-02463-4","volume":"60","author":"X Zhang","year":"2025","unstructured":"Zhang X, Xu K, Gale RP, Pan B. Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma. Bone Marrow Transplant. 2025 Feb;60(2):182-190. doi: 10.1038\/s41409-024-02463-4. Epub 2024 Nov 12. PMID: 39533016.","journal-title":"Bone Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06910-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:53Z","timestamp":1776405593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06910-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6910"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06910-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study was carried out after approval of the Ethics Committee of the Sichuan Cancer Hospital. Written informed consent was obtained from all participants prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"181"}}